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Tumor hypoxia predicts poor outcomes across all can-
cers and has long been recognized as a critical source of
resistance to both chemotherapy and radiotherapy.
Despite the success of T cell immune checkpoint block-
ade in treating melanoma, aggressive adenocarcinomas
of the prostate and pancreas are largely resistant to
CTLA-4 and PD-1 antibody therapy in the mouse and
in man. We find that hypoxic zones of these tumors
resist infiltration by T cells even in the context of robust
infiltration of T cells in normoxic areas of the same
tumor (e.g. in the context of T cell checkpoint block-
ade). Beyond this lack of accessibility to tumor-specific
T cells, hypoxia drives the establishment of a highly
interdependent network of immunosuppressive stromal
cells. Among these, we find myeloid-derived suppressor
cells and myofibroblasts to be the critical populations
which act together to suppress T cell responses and
mediate immunotherapy resistance.
Evofosfamide is a hypoxia-specific chemotherapeutic
pro-drug which is activated only in the hypoxic cores of
tumors and thus can be co-administered with immu-
notherapy. We find that Evofosfamide-driven disruption of
hypoxia zones sensitizes prostate cancer to antibody
blockade of CTLA-4 and PD-1 in both transplantable and
genetically-engineered murine models of prostate cancer.
Co-administration of Evofosfamide and a-CTLA-4/a-PD-
1 promotes tumor rejection in a significantly larger per-
centage of mice than either therapy alone. Mechanistic
studies reveals that loss of immune resistance is a conse-
quence of re-oxygenation of hypoxia zones which results
in 1) loss of active myeloid suppressor cells, 2) reduced
suppressive capacity of new myeloid immigrants, 3) loss of
suppressive activation of myofibroblasts, and 4) enhanced
infiltration of effector T cells. Therefore, this combination
of hypoxia disruption and T cell checkpoint blockade has
immense potential to render some of the most therapeuti-
cally resistant cancers sensitive to immunotherapy.
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